Harlan Waksal

Type: Person

Name: Harlan Waksal

First reported Mar 19 2013 - Updated Mar 19 2013 - 1 reports

Acasti Pharma Inc

Acasti's NKLP66 data show 23% triglyceride reduction

Acasti Pharma Inc. has provided encouraging preliminary clinical data of its randomized, open-label, dose-ranging, multicentre trial to assess the safety and efficacy of NKPL66 (CaPre) in the treatment of mild-to-high hypertriglyceridemia (open-label). ... [Published Stockwatch - Mar 19 2013]

Entities: Triglycerides, Harlan Waksal, Acasti Pharma Inc

First reported Jan 07 2013 - Updated Jan 07 2013 - 1 reports

Acasti Pharma Shares to Trade on NASDAQ

Easily Send & Share Press ReleasesLAVAL, Quebec, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc. ("Neptune") subsidiary, is pleased to announce that it has been approved ... [Published GlobeNewswire - Jan 07 2013]

Entities: Acasti Pharma Inc, Phospholipid, Omega-3 Fatty Acid, Stocks

Quotes

...the NASDAQ listing should be followed by the expected completion of the open label clinical trial," said Harlan Waksal, Executive Vice-President. "there are multiple us institutional funds that are restricted from investing in shares that trade on foreign exchanges. we therefore believe that acasti's nasdaq listing will broaden its base of potential shareholders" he added. Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids...

Acasti Pharma Shares to Trade on NASDAQ [Published GlobeNewswire - Jan 07 2013]